EAM
RCUS icon

Eventide Asset Management’s Arcus Biosciences RCUS Stock Holding History

Eventide Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-240,000
Closed -$4.53M – 169
2024
Q1 		$4.53M Hold
240,000
– – 0.07% 135
2023
Q4 		$4.58M Hold
240,000
– – 0.07% 134
2023
Q3 		$4.31M Hold
240,000
– – 0.08% 136
2023
Q2 		$4.87M Hold
240,000
– – 0.08% 128
2023
Q1 		$4.38M Hold
240,000
– – 0.08% 128
2022
Q4 		$4.96M Buy
+240,000
New +$6.6M 0.1% 124

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Eventide Asset Management's RCUS Position: Q2 2024 in Review

Eventide Asset Management sold out of Arcus Biosciences (RCUS) in Q2 2024, closing a stake of 240,000 shares — an estimated $4.53M sold.

Eventide Asset Management first reported a position in RCUS in Q4 2022 and held it in 6 quarters. The position peaked at $4.96M in Q4 2022. 193 funds tracked by Wall St. Rank hold RCUS as of Q2 2024.

  • Eventide Asset Management reported no remaining Arcus Biosciences position as of Q2 2024 after selling out during the quarter.
  • Eventide Asset Management sold 240,000 Arcus Biosciences shares in Q2 2024, an estimated $4.53M.
  • Eventide Asset Management first reported a position in Arcus Biosciences in Q4 2022 and held it in 6 quarters.
  • Eventide Asset Management's Arcus Biosciences position peaked at $4.96M in Q4 2022.
  • 193 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2024.

Based on Eventide Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.